1-2 of 2
Olivier Harismendy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR008: Duration of endocrine treatment for DCIS impacts second events: Insights from a large registry of cases at two academic medical centers

Thomas O'Keefe, Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim, Joseph McGuire, Ann Griffin, Laura Esserman, Olivier Harismendy, Gillian Hirst
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2022) 15 (12_Supplement_1): PR008.
https://doi.org/10.1158/1940-6215.DCIS22-PR008
Published: 01 December 2022
View articletitled, Abstract PR008: Duration of endocrine treatment for DCIS impacts second events: Insights from a large registry of cases at two academic medical centers
Journal Articles

HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence

Thomas J. O'Keefe, Sarah L. Blair, Ava Hosseini, Olivier Harismendy, Anne M. Wallace
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2020) 13 (9): 761–772.
https://doi.org/10.1158/1940-6207.CAPR-20-0024
Published: 02 September 2020
View articletitled, HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence
Open the PDF for HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence in another window